share_log

NexImmune | 8-K: Current report

NexImmune | 8-K: Current report

NexImmune | 8-K：重大事件
SEC announcement ·  04/05 16:10
Moomoo AI 已提取核心信息
On April 1, 2024, Timothy Stover, the Vice President, Corporate Controller, and the principal financial officer and principal accounting officer of NexImmune, Inc., announced his resignation effective April 16, 2024. The company clarified that Stover's departure was not due to any disagreements regarding operations, policies, or practices. Subsequently, on April 5, 2024, NexImmune's Board of Directors appointed Albert N. Marchio II as the Interim Chief Financial Officer. Marchio, with a 32-year tenure in the pharmaceutical industry, will assume the role of principal financial officer and principal accounting officer following Stover's departure. His previous experience includes roles at Danforth Advisors LLC, Fresh Tracks Therapeutics, Inc., and Edge Therapeutics, Inc., among others. The company has a Consulting Agreement with Danforth Advisors, which provides various services including the interim CFO services to be rendered by Marchio. The agreement also includes indemnification provisions and compensation on an hourly rate basis for services provided.
On April 1, 2024, Timothy Stover, the Vice President, Corporate Controller, and the principal financial officer and principal accounting officer of NexImmune, Inc., announced his resignation effective April 16, 2024. The company clarified that Stover's departure was not due to any disagreements regarding operations, policies, or practices. Subsequently, on April 5, 2024, NexImmune's Board of Directors appointed Albert N. Marchio II as the Interim Chief Financial Officer. Marchio, with a 32-year tenure in the pharmaceutical industry, will assume the role of principal financial officer and principal accounting officer following Stover's departure. His previous experience includes roles at Danforth Advisors LLC, Fresh Tracks Therapeutics, Inc., and Edge Therapeutics, Inc., among others. The company has a Consulting Agreement with Danforth Advisors, which provides various services including the interim CFO services to be rendered by Marchio. The agreement also includes indemnification provisions and compensation on an hourly rate basis for services provided.
2024年4月1日，NexImmune, Inc. 的副总裁、公司财务总监兼首席财务官兼首席会计官蒂莫西·斯托弗宣布辞职，自2024年4月16日起生效。该公司澄清说，斯托弗的离职不是由于在运营、政策或做法方面存在任何分歧。随后，NexImmune 董事会于 2024 年 4 月 5 日任命 Albert N. Marchio II 为临时首席财务官。在制药行业工作了32年的马尔基奥将在斯托弗离职后担任首席财务官和首席会计官一职。他之前的经历包括在丹佛斯顾问有限责任公司、Fresh Tracks Therapeutics, Inc.和Edge Therapeutics, Inc.等公司任职。该公司与Danforth Advisors签订了咨询协议，后者提供各种服务，包括由Marchio提供的临时首席财务官服务。该协议还包括赔偿条款和按小时费率对所提供服务的补偿。
2024年4月1日，NexImmune, Inc. 的副总裁、公司财务总监兼首席财务官兼首席会计官蒂莫西·斯托弗宣布辞职，自2024年4月16日起生效。该公司澄清说，斯托弗的离职不是由于在运营、政策或做法方面存在任何分歧。随后，NexImmune 董事会于 2024 年 4 月 5 日任命 Albert N. Marchio II 为临时首席财务官。在制药行业工作了32年的马尔基奥将在斯托弗离职后担任首席财务官和首席会计官一职。他之前的经历包括在丹佛斯顾问有限责任公司、Fresh Tracks Therapeutics, Inc.和Edge Therapeutics, Inc.等公司任职。该公司与Danforth Advisors签订了咨询协议，后者提供各种服务，包括由Marchio提供的临时首席财务官服务。该协议还包括赔偿条款和按小时费率对所提供服务的补偿。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息